Skip to main content

Table 1 Operating characteristics for the platform design with primary endpoint of major pathological response (MPR)

From: PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer

 

Control Arm

n = 30 for experimental arms

Experiment Arm 1

Experiment Arm 2

Experiment Arm 3

Experiment Arm 4

True MPR

0.130

0.195

0.260

0.130

0.300

Number of patients

42.6

30.0

30.0

30.0

30.0

Start Time (months)

0

0

6

12

18

Probability of claiming success

0.384

0.676

0.148

0.800